Shapiro Benjamin reported grant involving 72,780 shares of ORAMED PHARMACEUTICALS INC. on Nov 12, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
72,780Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
196,000Direct
Trade date
Nov 12, 2026Grant
Filed
Nov 13, 2026, 9:12 PM ET2-day reporting delay
Accession
0001213900-26-120038Code A · Transaction 401546
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Grant1,050——Trade 401547
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

ORMP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ORMP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 21, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +1.5%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 72,780 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual Board awards for fiscal years 2027 and 2028. Of these shares, 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2027, and 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2028, in each case subject to the reporting person's continued service. No annual Board award will be granted to the reporting person for fiscal year 2028. F2: On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 1,050 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's fiscal year 2027 committee awards, which vest in four substantially equal quarterly installments beginning April 1, 2027, subject to the reporting person's continued service. F3: These shares of Common Stock are held by a trust of which the reporting person is a trustee and beneficiary.